fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Mutual Funds » Best Pharma Mutual Funds

Top 4 Best Performing Pharma Mutual Funds 2025

Updated on April 3, 2025 , 204893 views

Pharma Mutual Funds are sector-specific fund that invests in different pharmaceutical companies.

Best Pharma Mutual Fund

Due to the huge population of India, there has always been a high demand for medicines and other health care needs because of which pharma companies have been earning good profits. Read this entire article to know the Indian Pharma sector, it's growth and the best Pharma mutual funds to Invest.

Pharma Sector in India

The pharmaceutical sector in India is one of the largest in the world and plays a significant role in the country's Economy. The Industry is known for its low-cost generic drug production and is considered as the "pharmacy of the world." The sector is highly regulated and governed by the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. India has a large number of domestic pharmaceutical companies, as well as several multinational corporations operating in the country. In recent years, the government of India has taken several initiatives to support the growth of the pharmaceutical sector, including tax incentives and investment in research and development.

India has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and about 10,500 Manufacturing units. The industry has been growing rapidly in recent years and has been making significant contributions to the country's economy through exports. According to a report by the Pharmaceuticals Export Promotion Council of India (Pharmexcil), the pharmaceutical exports from India reached around $19 billion in 2020, with the major export markets being the US, Europe, Africa, and Asia.

Largest pharmaceutical companies in India by Market capitalization (as of August 2021) are — Sun Pharmaceutical, Cipla, Lupin, Dr. Reddy’s Labs, Aurobindo Pharma, Divi's Laboratories, Torrent Pharmaceuticals, Glenmark Pharmaceuticals, etc.

If you are keen to invest in the pharma sector fund, the following are the schemes listed for you.

Pharma Equity Funds in India

Pharma funds belong to the equity sectoral fund category which mainly invests in pharma and pharma related stocks. They focus to create a long-term wealth for the investors by taking advantage of growth in the Pharmaceutical sector. In India, some of the top performing funds are - Nippon India Pharma Fund, TATA India Pharma & Healthcare Fund, UTI Healthcare Fund and SBI Healthcare Opportunities Fund.

Nippon India Pharma Fund is in the market since 2004 and has delivered 21.12% returns since inception, whereas UTI Healthcare Fund was launched in 2005 and delivered returns of 18.42% since inception.

SBI Healthcare Opportunities Fund is one of the oldest pharma fund, launched in the year 1999 and has delivered 15.59% returns since its launch.

The category average of pharma funds stood at 131.79% over 1 year period ended 5 March 2010. Three out of four funds have outpaced BSE Healthcare over the same time period. The Reliance India Pharma Fund has topped the category over one year period. The category average has been 19.77% and 18.81% during three years and five years time period.

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Best Pharma Sector Funds 2025

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2024 (%)
TATA India Pharma & Healthcare Fund Growth ₹28.0161
↓ -0.89
₹1,104-11.9-9.110.617.425.140.4
Nippon India Pharma Fund Growth ₹468.829
↓ -15.57
₹7,637-11.1-9.38.816.726.234
SBI Healthcare Opportunities Fund Growth ₹412.667
↑ 7.64
₹3,313-6.3-119.223.12942.2
UTI Healthcare Fund Growth ₹260.596
↓ -9.15
₹1,057-11.2-9.21617.926.142.9
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 4 Apr 25

1. TATA India Pharma & Healthcare Fund

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund was launched on 28 Dec 15. It is a fund with High risk and has given a CAGR/Annualized return of 11.8% since its launch.  Return for 2024 was 40.4% , 2023 was 36.6% and 2022 was -8% .

Below is the key information for TATA India Pharma & Healthcare Fund

TATA India Pharma & Healthcare Fund
Growth
Launch Date 28 Dec 15
NAV (04 Apr 25) ₹28.0161 ↓ -0.89   (-3.10 %)
Net Assets (Cr) ₹1,104 on 28 Feb 25
Category Equity - Sectoral
AMC Tata Asset Management Limited
Rating Not Rated
Risk High
Expense Ratio 0
Sharpe Ratio 0.04
Information Ratio 0.42
Alpha Ratio 0.96
Min Investment 5,000
Min SIP Investment 150
Exit Load 0-3 Months (0.25%),3 Months and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Mar 20₹10,000
31 Mar 21₹16,489
31 Mar 22₹19,237
31 Mar 23₹17,775
31 Mar 24₹28,060
31 Mar 25₹32,066

TATA India Pharma & Healthcare Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹570,326.
Net Profit of ₹270,326
Invest Now

Returns for TATA India Pharma & Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 4 Apr 25

DurationReturns
1 Month 4.6%
3 Month -11.9%
6 Month -9.1%
1 Year 10.6%
3 Year 17.4%
5 Year 25.1%
10 Year
15 Year
Since launch 11.8%
Historical performance (Yearly) on absolute basis
YearReturns
2024 40.4%
2023 36.6%
2022 -8%
2021 19.1%
2020 64.4%
2019 5.5%
2018 -2.6%
2017 4.7%
2016 -14.7%
2015
Fund Manager information for TATA India Pharma & Healthcare Fund
NameSinceTenure
Meeta Shetty9 Mar 214.06 Yr.
Rajat Srivastava16 Sep 240.54 Yr.

Data below for TATA India Pharma & Healthcare Fund as on 28 Feb 25

Equity Sector Allocation
SectorValue
Health Care95.87%
Basic Materials2.19%
Asset Allocation
Asset ClassValue
Cash1.94%
Equity98.06%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMA
12%₹128 Cr804,300
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | DRREDDY
7%₹80 Cr714,555
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 30 Apr 20 | AUROPHARMA
7%₹78 Cr741,000
Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | 500087
6%₹69 Cr490,000
Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | 500257
6%₹69 Cr360,240
Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB
5%₹58 Cr104,965
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Oct 20 | 532843
5%₹52 Cr855,100
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSP
4%₹44 Cr72,635
↑ 13,732
Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Dec 22 | 532321
4%₹41 Cr471,287
Aster DM Healthcare Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Dec 22 | ASTERDM
3%₹37 Cr906,991
↑ 250,000

2. Nippon India Pharma Fund

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund was launched on 5 Jun 04. It is a fund with High risk and has given a CAGR/Annualized return of 20.3% since its launch.  Ranked 35 in Sectoral category.  Return for 2024 was 34% , 2023 was 39.2% and 2022 was -9.9% .

Below is the key information for Nippon India Pharma Fund

Nippon India Pharma Fund
Growth
Launch Date 5 Jun 04
NAV (04 Apr 25) ₹468.829 ↓ -15.57   (-3.21 %)
Net Assets (Cr) ₹7,637 on 28 Feb 25
Category Equity - Sectoral
AMC Nippon Life Asset Management Ltd.
Rating
Risk High
Expense Ratio 1.88
Sharpe Ratio -0.03
Information Ratio -0.33
Alpha Ratio -3.9
Min Investment 5,000
Min SIP Investment 100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Mar 20₹10,000
31 Mar 21₹17,447
31 Mar 22₹20,234
31 Mar 23₹18,871
31 Mar 24₹29,909
31 Mar 25₹33,564

Nippon India Pharma Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹584,107.
Net Profit of ₹284,107
Invest Now

Returns for Nippon India Pharma Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 4 Apr 25

DurationReturns
1 Month 2.5%
3 Month -11.1%
6 Month -9.3%
1 Year 8.8%
3 Year 16.7%
5 Year 26.2%
10 Year
15 Year
Since launch 20.3%
Historical performance (Yearly) on absolute basis
YearReturns
2024 34%
2023 39.2%
2022 -9.9%
2021 23.9%
2020 66.4%
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%
Fund Manager information for Nippon India Pharma Fund
NameSinceTenure
Sailesh Raj Bhan1 Apr 0520.01 Yr.
Kinjal Desai25 May 186.86 Yr.

Data below for Nippon India Pharma Fund as on 28 Feb 25

Equity Sector Allocation
SectorValue
Health Care98.89%
Asset Allocation
Asset ClassValue
Cash1.11%
Equity98.89%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
14%₹1,045 Cr6,556,349
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
9%₹712 Cr1,298,808
↓ -52,000
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257
8%₹590 Cr3,098,126
↓ -102,567
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087
6%₹450 Cr3,200,000
↑ 100,000
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY
5%₹409 Cr3,662,170
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP
5%₹393 Cr648,795
Abbott India Ltd (Healthcare)
Equity, Since 31 May 11 | ABBOTINDIA
4%₹292 Cr95,985
↑ 9,595
Vijaya Diagnostic Centre Ltd (Healthcare)
Equity, Since 30 Sep 21 | 543350
3%₹260 Cr2,843,231
Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | 543427
3%₹259 Cr3,627,277
↑ 62,597
GlaxoSmithKline Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Aug 22 | GLAXO
3%₹250 Cr1,011,921
↑ 179,134

3. SBI Healthcare Opportunities Fund

(Erstwhile SBI Pharma Fund)

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy.

SBI Healthcare Opportunities Fund is a Equity - Sectoral fund was launched on 31 Dec 04. It is a fund with High risk and has given a CAGR/Annualized return of 15.6% since its launch.  Ranked 34 in Sectoral category.  Return for 2024 was 42.2% , 2023 was 38.2% and 2022 was -6% .

Below is the key information for SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund
Growth
Launch Date 31 Dec 04
NAV (03 Apr 25) ₹412.667 ↑ 7.64   (1.89 %)
Net Assets (Cr) ₹3,313 on 28 Feb 25
Category Equity - Sectoral
AMC SBI Funds Management Private Limited
Rating
Risk High
Expense Ratio 2.09
Sharpe Ratio 0.35
Information Ratio 0.73
Alpha Ratio 2.13
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-15 Days (0.5%),15 Days and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Mar 20₹10,000
31 Mar 21₹17,177
31 Mar 22₹19,486
31 Mar 23₹19,107
31 Mar 24₹30,178
31 Mar 25₹36,162

SBI Healthcare Opportunities Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹612,552.
Net Profit of ₹312,552
Invest Now

Returns for SBI Healthcare Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 4 Apr 25

DurationReturns
1 Month 7.4%
3 Month -6.3%
6 Month -1%
1 Year 19.2%
3 Year 23.1%
5 Year 29%
10 Year
15 Year
Since launch 15.6%
Historical performance (Yearly) on absolute basis
YearReturns
2024 42.2%
2023 38.2%
2022 -6%
2021 20.1%
2020 65.8%
2019 -0.5%
2018 -9.9%
2017 2.1%
2016 -14%
2015 27.1%
Fund Manager information for SBI Healthcare Opportunities Fund
NameSinceTenure
Tanmaya Desai1 Jun 1113.84 Yr.

Data below for SBI Healthcare Opportunities Fund as on 28 Feb 25

Equity Sector Allocation
SectorValue
Health Care90.4%
Basic Materials6.89%
Asset Allocation
Asset ClassValue
Cash2.62%
Equity97.29%
Debt0.09%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA
13%₹446 Cr2,800,000
Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH
6%₹215 Cr2,200,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
6%₹206 Cr375,000
↓ -15,000
Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | 500087
5%₹169 Cr1,200,000
Lonza Group Ltd ADR (Healthcare)
Equity, Since 31 Jan 24 | LZAGY
5%₹166 Cr300,000
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 23 | 500257
5%₹160 Cr840,000
Mankind Pharma Ltd (Healthcare)
Equity, Since 30 Apr 23 | MANKIND
4%₹128 Cr560,000
Aether Industries Ltd (Basic Materials)
Equity, Since 31 May 22 | 543534
4%₹120 Cr1,400,000
Jupiter Life Line Hospitals Ltd (Healthcare)
Equity, Since 31 Aug 23 | JLHL
3%₹115 Cr800,000
Poly Medicure Ltd (Healthcare)
Equity, Since 31 Aug 24 | POLYMED
3%₹110 Cr540,000
↑ 40,000

4. UTI Healthcare Fund

(Erstwhile UTI Pharma & Healthcare Fund)

The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.

UTI Healthcare Fund is a Equity - Sectoral fund was launched on 28 Jun 99. It is a fund with High risk and has given a CAGR/Annualized return of 14.7% since its launch.  Ranked 40 in Sectoral category.  Return for 2024 was 42.9% , 2023 was 38.2% and 2022 was -12.3% .

Below is the key information for UTI Healthcare Fund

UTI Healthcare Fund
Growth
Launch Date 28 Jun 99
NAV (04 Apr 25) ₹260.596 ↓ -9.15   (-3.39 %)
Net Assets (Cr) ₹1,057 on 28 Feb 25
Category Equity - Sectoral
AMC UTI Asset Management Company Ltd
Rating
Risk High
Expense Ratio 2.38
Sharpe Ratio 0.28
Information Ratio -0.09
Alpha Ratio 1.36
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Mar 20₹10,000
31 Mar 21₹17,396
31 Mar 22₹19,596
31 Mar 23₹17,899
31 Mar 24₹27,884
31 Mar 25₹33,479

UTI Healthcare Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹584,107.
Net Profit of ₹284,107
Invest Now

Returns for UTI Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 4 Apr 25

DurationReturns
1 Month 4.3%
3 Month -11.2%
6 Month -9.2%
1 Year 16%
3 Year 17.9%
5 Year 26.1%
10 Year
15 Year
Since launch 14.7%
Historical performance (Yearly) on absolute basis
YearReturns
2024 42.9%
2023 38.2%
2022 -12.3%
2021 19.1%
2020 67.4%
2019 1.2%
2018 -7.5%
2017 6.2%
2016 -9.7%
2015 12.4%
Fund Manager information for UTI Healthcare Fund
NameSinceTenure
Kamal Gada2 May 222.83 Yr.

Data below for UTI Healthcare Fund as on 28 Feb 25

Equity Sector Allocation
SectorValue
Health Care98.22%
Basic Materials1.33%
Asset Allocation
Asset ClassValue
Cash0.45%
Equity99.55%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA
11%₹116 Cr725,000
Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 500087
6%₹65 Cr464,949
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDY
5%₹48 Cr432,608
↓ -37,626
Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 532331
4%₹47 Cr188,399
↑ 1,601
Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | 532296
4%₹40 Cr309,311
Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND
4%₹37 Cr240,012
↓ -465
Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHL
4%₹37 Cr74,000
Suven Pharmaceuticals Ltd (Healthcare)
Equity, Since 28 Feb 21 | SUVENPHAR
3%₹36 Cr295,000
↑ 2,080
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | 532843
3%₹34 Cr557,701
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP
3%₹34 Cr56,271

Nifty Pharma Index

Generally Pharma Mutual funds follow similar composition of stocks tracking Nifty Pharma Index or CNX Pharma Index as this index is benchmark for Pharma Sector Mutual Funds. Although Pharma Mutual Funds might not necessarily replicate same ratios and components.

Portfolio Characteristics

Portfolio Characteristics
Methodology Periodic Capped Free Float
Launch Date July 01, 2005
Base Date Jan 01, 2001
Base Value 1000
No. of Constituents 20
Calculation Frequency Real Time
Index Rebalancing Semi-Annually

Top Constituents by Weightage

Constituents companies of Nifty Pharma Index with weightage

As on Jan, 2023

Stock Weightage
Sun Pharmaceutical Industries Ltd. 26.88
Cipla Ltd. 13.25
Dr. Reddy's Laboratories Ltd. 12.65
Divi's Laboratories Ltd. 10.17
Lupin Ltd. 4.28
Alkem Laboratories Ltd. 3.55
Torrent Pharmaceuticals Ltd. 3.35
Laurus Labs Ltd. 3.12
Ipca Laboratories Ltd. 2.80
Aurobindo Pharma Ltd. 2.76

To more about index can be read on official website Nifty Pharma Index Document

Who Should Invest in Pharma Mutual Funds?

Being a sector-specific fund, pharma funds carry a huge risk of investment. Investors having an in-depth knowledge of the pharma and healthcare industry are only advised to invest. Also, the ability to bear a high-risk. Investors who think the pharma sector will give good returns in the future or can perform stable in the long-run can invest.

Healthcare Sector in India

1. Public Healthcare

Public healthcare is free for those who are below the poverty line. It encompasses 18% of total outpatient care and 44% of total inpatient care. Middle and upper class individuals tend to use public healthcare less than those with a lower standard of living. Additionally, females and elderly use public services more. The public health care system was originally developed in order to provide a means to healthcare access regardless of socioeconomic status. However, reliance on public and private healthcare sectors varies significantly between states. Several reasons are cited for relying on the private rather than public sector; the main reason at the national level is poor quality of care in the public sector, with more than 57% of households pointing to this as the reason for a preference for private health care.

Most of the public healthcare caters to the rural areas; and the poor quality arises from the reluctance of experienced healthcare providers to visit the rural areas. Consequently, the majority of the public healthcare system catering to the rural and remote areas relies on inexperienced and unmotivated interns who are mandated to spend time in public healthcare clinics as part of their curricular requirement. Other major reasons are distance of the public sector Facility, long wait times, and inconvenient hours of operation.

Different factors related to public healthcare are divided between the state and national government systems in terms of making decisions, as the national government addresses broadly applicable healthcare issues such as overall family welfare and prevention of major diseases, while the state governments Handle aspects such as local hospitals, public health, promotion and sanitation, which differ from state to state based on the particular communities involved. Interaction between the state and national governments does occur for healthcare issues that require larger scale resources or present a concern to the country as a whole.

2. Private healthcare

Since 2005, most of the healthcare capacity added has been in the private sector, or in partnership with the private sector. The private sector consists of 58% of the hospitals in the country, 29% of beds in hospitals, and 81% of doctors. According to National Family Health Survey-3, the private medical sector remains the primary source of health care for 70% of households in urban areas and 63% of households in rural areas. The study conducted by IMS Institute for Healthcare Informatics in 2013, across 12 states in over 14,000 households indicated a steady increase in the usage of private healthcare facilities over the last 25 years for both Out Patient and In Patient services, across rural and urban areas. In terms of healthcare quality in the private sector, a 2012 study by Sanjay Basu et al., published in PLOS Medicine, indicated that health care providers in the private sector were more likely to spend a longer duration with their patients and conduct physical exams as a part of the visit compared to those working in public healthcare.

However, the high out of pocket cost from the private healthcare sector has led many households to incur Catastrophic Health Expenditure, which can be defined as health expenditure that threatens a household's capacity to maintain a basic standard of living. Costs of the private sector are only increasing. One study found that over 35% of poor Indian households incur such expenditure and this reflects the detrimental state in which Indian health care system is at the moment.

With government expenditure on health as a percentage of GDP falling over the years and the rise of private health care sector, the poor are left with fewer options than before to access health care services. Private insurance is available in India, as are various through government-sponsored health insurance schemes. According to the World Bank, about 25% of India's population had some form of health insurance in 2010. 2014 Indian government study found this to be an over-estimate, and claimed that only about 17% of India's population was insured.

How to Invest in Pharma Sector Funds Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.

  2. Complete your Registration and KYC Process

  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest!

    Get Started

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data. Please verify with scheme information document before making any investment.
How helpful was this page ?
Rated 4.4, based on 51 reviews.
POST A COMMENT

Yogesh Kumar Juneja , posted on 5 Sep 21 7:00 AM

Please send list of funds which has the option of changing the sector of funds so that overall performance of mutual funds are always very good. Thanks and Regards

Shailendra, posted on 24 Jul 19 2:32 PM

Are largecap is best investment on longterm

1 - 2 of 2